[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"copd\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:copd":28},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,210,0,25,[9,42,75,98,126,154,182,208,239,268,287,308,336,356,382,408,430,454,474,498,520,546,570,596,623],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100643516","phase-2-a-clinical-trial-to-evaluate-the-efficacy-and-safety-of-hrs-9821-inhalation-suspension-in-patients-with-moderate-to-severe-chronic-obstructive-pulmonary-disease-100643516",false,"NCT07640451","A Clinical Trial to Evaluate the Efficacy and Safety of HRS-9821 Inhalation Suspension in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease","A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Clinical Trial to Evaluate the Efficacy and Safety of HRS-9821 Inhalation Suspension in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease","Inclusion Criteria:\n\n1. Age ≥ 40 years old and \\\u003C 80 years old, male or female.\n2. Meet the weight standard.\n3. Smoking history ≥ 10 pack-years.\n4. COPD has been diagnosed ≥ 1 year.\n5. 4 weeks before screening, the background treatment for COPD was stable.\n6. FEV1\u002FFVC \\\u003C 0.7, 30% ≤ FEV1 ≤ 80%.\n7. mMRC score ≥ 2.\n8. The inspection and medication can be completed as required.\n9. Non-pregnant and breastfeeding state.\n10. Able and willing to provide a written informed consent.\n\nExclusion Criteria:\n\n1. History of life-threatening COPD.\n2. Other pulmonary diseases that may affect the efficacy evaluation of this study.\n3. Concurrent diseases other than COPD that may affect lung function.\n4. History of asthma.\n5. Pulmonary heart disease requiring clinical intervention, or moderate to severe pulmonary hypertension.\n6. Malignant tumors within 5 years.\n7. Uncontrolled severe cardiovascular and cerebrovascular diseases within 1 year.\n8. Unstable diseases.\n9. Acute exacerbation of COPD within 12 weeks, hospitalization for COPD or pneumonia within 6 months.\n10. Infection in the lungs or other parts occurs within 16 weeks and requires treatment.\n11. Immunosuppression.\n12. Uncontrolled hypertension.\n13. Lung resection, surgical lung volume reduction or endoscopic treatment for COPD.\n14. Undergone major surgery or planned surgery within 14 months.\n15. Abnormal chest images have clinical significance.\n16. Tuberculosis infection requiring treatment within 16 to 12 months.\n17. Virological test result was positive.\n18. Laboratory blood tests and electrocardiograms were significantly abnormal.\n19. Requires oxygen inhalation or intermittent oxygen inhalation therapy.\n20. Hypercapnia, using or requiring long-term use of any non-invasive positive pressure ventilation device.\n21. Biological agents that may have therapeutic effects on the studied disease have been used within 12 weeks or within 5 half-lives of the drug.\n22. Vaccination, theophylline or drugs within 4 weeks.\n23. Having participated in other clinical studies within 4 weeks and used research drugs or medical devices containing active ingredients, or still within 5 half-lives of the research drug.\n24. Systemic glucocorticoids, immunosuppressants, and oral Roflumilast within 12 weeks.\n25. Undergoing or planning rehabilitation treatment for pulmonary rehabilitation.\n26. Non-selective β blockers within 1 week.\n27. Overly potent\u002Fmoderately potent drugs that inhibit or induce the liver drug-metabolizing enzyme CYP3A4 within 14 days.\n28. Allergic to the research drug or salbutamol or excipients.\n29. Has been used HRS-9821.\n30. Drug abuse and alcohol abuse within 1 year.\n31. Pregnant or lactating period or planning to be pregnant or lactating.\n32. The researchers judged that there were other unsuitable circumstances.","ALL","40 Years","80 Years",{"count":21,"type":22},90,"ESTIMATED","INTERVENTIONAL",[25],"PHASE2","The study is being conducted to evaluate the efficacy and safety of HRS-9821 for patients with COPD, and to explore the reasonable dosage of HRS-9821 for patients with COPD.",[28],"COPD","RECRUITING","2026-08-17",{"date":32,"type":33},"2026-08-18","ACTUAL",{"date":35,"type":33},"2026-07-20",{"date":37,"type":22},"2026-11",{"name":39,"class":40},"Guangdong Hengrui Pharmaceutical Co., Ltd","INDUSTRY",1,{"id":43,"slug":44,"hasResults":12,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":23,"phases":52,"briefSummary":54,"conditions":55,"keywords":61,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":74},"100650653","balance-training-following-pulmonary-rehabilitation-on-balance-in-people-with-chronic-obstructive-pulmonary-disease-copd-100650653","NCT07750821","Balance Training Following Pulmonary Rehabilitation on Balance in People With Chronic Obstructive Pulmonary Disease (COPD)","A Pilot Feasibility, Multi-centre, Randomised Controlled Trial of Balance Training Following Pulmonary Rehabilitation on Balance in People With Chronic Obstructive Pulmonary Disease (COPD)","B-PuRe","Inclusion Criteria:\n\n1. Adults with spirometry confirmed diagnosis of COPD as per GOLD guidelines (FEV1\u002FFVC ratio below 0.7) or physician confirmed COPD diagnosis\n2. Answers yes to one or more of the Three Key Questions\\* or Timed up and Go Test result \\> 11 seconds\n3. An ability and capacity to provide consent to the trial\n\n   * Q1. Have you fallen in the past year? Q2. Do you feel unsteady when standing or walking? Q3. Do you have worries about falling?\n\nExclusion Criteria:\n\n1. Any neurological, musculoskeletal, chronic pain or other diagnoses that, in the opinion of the investigator, would interfere with the ability of the participant to safely complete PR and balance training\n2. Unable to comprehend instruction given verbally in English language\n3. Where there is concern that the primary cause of balance issues could be due to problems with visual function, vestibular disturbance or peripheral neuropathy\n4. Diagnosis of, or patient-reported symptoms of, vasovagal syncope",{"count":51,"type":22},77,[53],"NA","This study aims to see if a co-designed balance training programme called Sport4Steadiness (S4S), is acceptable to people with COPD and if the study procedures, including recruitment and the collection of outcomes, is feasible.",[56,28,57,58,59,60],"COPD (Chronic Obstructive Pulmonary Disease)","Balance Exercise","Falls, Intervention","Balance Training","Pulmonary Rehabilitation",[48,62,63,28],"Balance","Pulmonary rehabilitation","2026-08-12",{"date":66,"type":33},"2026-08-14",{"date":68,"type":33},"2026-01-27",{"date":70,"type":22},"2027-05-01",{"name":72,"class":73},"Samantha Harrison","OTHER",3,{"id":76,"slug":77,"hasResults":12,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":81,"eligibilityCriteria":82,"healthyVolunteers":12,"sex":17,"minAge":83,"maxAge":19,"enrollmentInfo":84,"targetDuration":4,"studyType":86,"phases":4,"briefSummary":87,"conditions":88,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":91,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":41},"100477875","relationship-of-inflammation-and-pulmonary-function-to-fungal-translocation-in-hiv-100477875","NCT05502653","Relationship of Inflammation and Pulmonary Function to Fungal Translocation in HIV","Relationship of Fungal Translocation, Inflammation, and Pulmonary Function in HIV","RIFFT","Inclusion Criteria:\n\n* Age 18 to 80\n* HIV positive\n* Virally-suppressed on ART for at least 6 months\n* subjects enrolled in Dr. Morris's HLRC Studies STUDY20020151, STUDY19080258, STUDY19060243, STUDY19070181, STUDY19070181, STUDY19050326 OR subjects being seen at the HIV\u002FPACT clinics.\n\nExclusion Criteria:\n\n* Contraindication to pulmonary function testing (i.e., abdominal or cataract surgery within 3 months, recent myocardial infarction, etc.).\n* individuals with clinical or radiographic evidence of another significant pulmonary diagnosis (e.g. interstitial lung disease, active asthma)\n* inflammatory bowel disease\n* pregnancy\n* use of antibiotics in the prior 2 weeks\n* immunomodulators in the prior 6 months\n* unable to perform any study procedures.","18 Years",{"count":85,"type":22},100,"OBSERVATIONAL","The investigator will study the origin of fungal translocation in HIV, its relationship to the mycobiome, and its relationship to lung function and inflammation. Supported by the preliminary data and published studies, this project is based on the premise that circulating BDG derived from microbial translocation stimulates inflammation and worsens lung function in PWH.\n\nChronic obstructive pulmonary disease (COPD) is a significant public health problem with few therapies that modify disease trajectory. COPD is a leading cause of mortality in the United States associated with increased morbidity and healthcare costs. Long-acting bronchodilators and inhaled corticosteroids are mainstays of therapy that control symptoms and reduce acute exacerbation frequency, but do not have a significant impact on mortality or lung function trajectory. The National Heart, Lung, and Blood Institute's COPD National Action Plan focuses on the critical need for research to characterize COPD risk factors and disease mechanisms in order to improve the understanding of causes and progression of disease. The ultimate goal is to provide precision therapy to appropriate patient subgroups to preserve health or arrest disease progression.\n\nMicrobial organisms in the gut may have a profound effect on lung disease. The role of the gut-lung axis, defined as the cross-talk between gut microbiota and the lungs, in the pathogenesis of chronic respiratory diseases is emerging as an area of interest. Perturbations of gut microbiota characterized by low microbial diversity and changes in microbiota abundance are linked to childhood asthma risk, airflow obstruction in adult asthma, and severe lung dysfunction in cystic fibrosis. Studies in animals show that both a high fiber diet that modulates gut microbiota and an abundance of beneficial bacterial strains attenuate inflammation, emphysema, and COPD development in response to cigarette smoke exposure in murine models. In humans, recent investigations show differences in the gut microbial communities between COPD patients and healthy individuals as well as shifts in the gut microbiome with acute exacerbations of COPD.",[89,90,28],"HIV Infections","Inflammation",{"date":66,"type":33},{"date":93,"type":33},"2022-09-01",{"date":95,"type":22},"2027-11-01",{"name":97,"class":73},"University of Pittsburgh",{"id":99,"slug":100,"hasResults":12,"nctId":101,"briefTitle":102,"officialTitle":103,"acronym":4,"eligibilityCriteria":104,"healthyVolunteers":105,"sex":17,"minAge":83,"maxAge":19,"enrollmentInfo":106,"targetDuration":4,"studyType":23,"phases":108,"briefSummary":110,"conditions":111,"keywords":114,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":120,"completionDateStruct":122,"leadSponsor":124,"locationsCount":41},"100614863","phase-1-inhaled-rb042-in-healthy-adult-volunteers-and-healthy-adult-smokers-100614863","NCT07285122","Inhaled RB042 in Healthy Adult Volunteers, Healthy Adult Smokers and Patients With Chronic Obstructive Pulmonary Disease","A Phase 1a\u002F1b, Randomised, Double Blind, Placebo-controlled, Dose-escalating Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of RB042 Administered Via Inhalation to Healthy Adult Volunteers, Healthy Adult Smokers and Patients With Chronic Obstructive Pulmonary Disease","Inclusion Criteria:\n\n* Part A, B, C only: Participants must be 18 to 55 years of age inclusive.\n* Part D only: Patients must be 40 to 80 years of age inclusive.\n* Part A, B, C only: Participants must be overtly healthy as determined by medical evaluation.\n* Part C only: have a ≥10 pack years smoking history, have smoked tobacco products (cigarettes, cigars, or equivalent) regularly for the past 12 months, and currently smoke daily.\n* Part D only: Former smokers (smoked a total of 100 or more cigarettes in their lifetime but has not smoked in the past 6 months to over a year).\n* Part A, B, C only: Have forced expiratory volume (FEV1) ≥80% predicted and FEV1 to FVC ratio (FEV1\u002FFVC) ≥0.7 at Screening and on Day -1.\n* Part D only: Have forced expiratory volume (FEV1) between ≥30% and \\\u003C80% predicted and FEV1 to FVC ratio (FEV1\u002FFVC) \\\u003C0.7 post-bronchodilation at Screening.\n* Part D only: Documented clinical diagnosis of COPD per 2026 Global Initiative for Chronic Obstructive Lung Disease (GOLD) for greater than ≥1 year and a history of chronic bronchitis as evidenced by frequent productive cough in the 2-year period immediately before Screening.\n* Part D only: Have clinically stable COPD with no moderate to severe exacerbations in the past 3 months.\n* Part D only: Must be on stable assigned maintenance COPD therapy.\n* Body weight at least 50 kg and have a body mass index (BMI) within the range 18.0 and 32.0 kg\u002Fm2 (inclusive)\n* Women of childbearing potential (WOCBP) must have a negative pregnancy test and must not be lactating.\n* Participants must agree to use an approved method(s) of highly effective contraception as defined in the protocol.\n\nExclusion Criteria:\n\n* Part A, B and C only: Clinically significant history or presence of gastrointestinal, hepatic, renal, cardiovascular, respiratory, endocrine, neurologic, hematologic, metabolic, autoimmune, or oncologic disorders that may affect safety or study outcomes.\n* Part D only: Current unstable clinically significant history or presence of gastrointestinal, hepatic, renal, cardiovascular, respiratory, endocrine, neurologic, hematologic, metabolic, autoimmune, or oncologic disorders that may affect safety or study outcomes.\n* Part A, B and C only: Chronic or active respiratory disease (e.g., asthma, COPD) or history of angioedema within 3 years.\n* Part D only: Patients with other respiratory conditions other than COPD (for example, clinically significant asthma, active tuberculosis, pulmonary fibrosis) are excluded if these conditions are the primary cause of their respiratory symptoms.\n* Active or chronic liver disease, or abnormal liver function tests (ALT, AST, or bilirubin outside reference range, except Gilbert's syndrome).\n* QTcF \\>450 msec (males) or \\>470 msec (females).\n* Renal impairment (creatinine clearance \\\u003C90 mL\u002Fmin) or thrombocytopenia (\\\u003C150 × 10⁹\u002FL).\n* Positive test for hepatitis B surface or core antigen, hepatitis C (unless HCV-RNA negative), or HIV.\n* Active respiratory infection within 5 days before study start.\n* Recent or concurrent use of medications, herbal supplements, vaccines, or blood products that could interfere with study safety or interpretation.\n* Participation in another investigational study within 30 days, or blood donation \\>400 mL within 30 days.\n* Parts A, B and D only: Regular smoking (≥1 day per week) within 6 months prior to dosing, or a positive urine cotinine test at screening or Day -1.\n* Excessive alcohol consumption (\\>21 drinks\u002Fweek for males or \\>14 for females).\n* History of severe drug reaction or anaphylaxis.\n* Part B and C only: Contraindication to, or unwillingness to undergo, bronchoscopy.\n* Any psychiatric or medical condition that, in the investigator's opinion, could compromise safety or compliance.",true,{"count":107,"type":22},105,[109],"PHASE1","This is a 4-part, randomised, double-blind, placebo-controlled, first in human study evaluating the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of inhaled RB042.",[112,113,56,28],"Healthy","Healthy Smoker",[28,115,116,117],"Chronic Obstructive Pulmonary Disease","Healthy smoker","Healthy volunteer","2026-08-10",{"date":64,"type":33},{"date":121,"type":33},"2026-02-16",{"date":123,"type":22},"2027-10",{"name":125,"class":40},"Atisama Therapeutics",{"id":127,"slug":128,"hasResults":12,"nctId":129,"briefTitle":130,"officialTitle":130,"acronym":131,"eligibilityCriteria":132,"healthyVolunteers":12,"sex":17,"minAge":133,"maxAge":4,"enrollmentInfo":134,"targetDuration":4,"studyType":23,"phases":136,"briefSummary":137,"conditions":138,"keywords":140,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":145,"lastUpdatePostDateStruct":146,"startDateStruct":148,"completionDateStruct":150,"leadSponsor":152,"locationsCount":74},"100604139","app-based-medical-device-for-education-and-training-of-inhalation-technique-100604139","NCT07145632","APP-based Medical Device for Education and Training of Inhalation Technique","APPETITE","Inclusion Criteria:\n\n* Subjects at age \\>16 years\n* Willing to voluntarily participate in the study and give electronic written informed consent\n* Prescribed with daily inhalation therapy through DPI and\u002For MDI for doctor's diagnosed asthma or COPD.\n\nExclusion Criteria:\n\n* Age \\\u003C16 years,\n* No access to smartphone of type Android or iPhone\n* No access to electronic signature for informed consent\n* Plan to withdraw inhaler treatment including daily DPI and\u002For MDI the following 6-12 weeks.\n* Medical condition affecting the ability to independently inhale or use DPI or MDI device(s).","16 Years",{"count":135,"type":22},80,[53],"Primary aim: To investigate if app-based education and training of inhalation technique improves the rate of successful inhalation techniques compared with control group at 6-12 weeks follow-up visit.\n\nSecondary aims: To evaluate the feasibility, usability, and safety of the investigational during the study period.\n\nStudy design: Two-armed, parallel-designed, individual single-blinded stratified randomisation by inhaler (DPI\u002FMDI\u002Fboth DPI and MDI) controlled trial with assignment (1:1) to (1) standard care and app-based education and training of inhalation technique or (2) standard education of inhalation technique over 6-12 weeks.\n\nSubjects: Subjects from the age of 16 years with documented diagnosis of asthma and\u002For COPD, daily treated with dry powder inhaler (DPI) or metered dose inhaler (MDI), or both, will be invited to voluntarily participate. Exclusion criteria is age \\\u003C16 years, no access to use BankID or similar electronic personal identification service, not using smartphone of type Android or iPhone, plan to stop use DPI and\u002For MDI the following 6-12 weeks from inclusion. No able to independently handle and inhale through DPI or MDI device.\n\nTotal sample size: Eighty subjects (females and males) with daily treatment for COPD or asthma will be sufficient, based on the assumption of 25% percentage improvement in success rate of correct inhalation technique in the interventional group compared with control group (75% versus 50%) with 80% power at 5% significance level, including dropouts at 6-12 weeks follow-up visit.\n\nIntervention: At the baseline visit patients will be randomised to app-based intervention consisting of education and training of inhalation technique of all inhalers used on daily basis (the inhalation app-module). Stratified randomisation based on type of inhaler(s); MDI, DPI or both MDI and DPI will be applied. The intervention is the inhalation app-module, which is a medical device that is embedded the AsthmaTuner app. The AsthmaTuner app is a CE-marked cloud-based system (MDR Class 2b), provided by MediTuner AB, Stockholm, Sweden. The intervention group will be instructed to use the inhalation app-module on daily basis to improve their inhalation technique.\n\nControl group: Standard education of inhalation technique using list of standardised criteria and non-app-based education of inhaler technique.\n\nEndpoints: Primary endpoint is the rate of subjects with successful inhalation techniques based on subjective critical endpoints (CIP Table 2) and the following objective endpoints at the 6-12 weeks follow up visit:\n\n* DPI: PIF \\> 30 L\u002FMin, time to PIF \\\u003C0.5 seconds measured with the investigational device.\n* MDI: inspiration time (\\> 3 seconds) and PIF less than 60 L\u002FMin measured with the investigational device.\n\nProcedures: At baseline, a trained respiratory nurse will subjectively assess and train each patient's inhalation technique according to defined criteria of device handling (standard education). The AsthmaTuner app is downloaded to a smartphone or tablet computer (Ipad) that is wirelessly (Bluetooth) connected to a home spirometer. In this study the Bluetooth spirometer AsthmaTuner from MIR will be used. Education and training of inhalation technique will include measurement of inhalation flow with an adjustable resistance mounted on the spirometer, Airflow Trainer (MIR). The app gives instruction to set the resistance, so it corresponds to the selected inhaler. Questionnaires and interviews will collect information about the feasibility, safety and experienced usability of the investigational device.\n\nAnalysis: The rate of subjects with successful inhalation technique at 6-12-week visit determined by fulfilling objective and subjective critical endpoints in intention-to-treat approach. The effect of using the inhalation app-module will be analysed with logistic regression analysis across randomisation groups. The secondary analysis of feasibility and the experienced benefit of using the inhalation app-module in clinical practice and for patient's education and training of inhalation technique is estimated on a Likert scale from 1 (not at all) to 5 (strongly agree) and presented as mean and median scores.",[139,28],"Asthma (Part 1)",[141,142,143,144],"Management","Inhaler technique","Metered Dose Inhaler - MDI","Dry Powder Inhaler - DPI","2026-08-04",{"date":147,"type":33},"2026-08-07",{"date":149,"type":33},"2025-06-01",{"date":151,"type":22},"2027-06-01",{"name":153,"class":73},"Karolinska Institutet",{"id":155,"slug":156,"hasResults":12,"nctId":157,"briefTitle":158,"officialTitle":159,"acronym":160,"eligibilityCriteria":161,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":162,"targetDuration":4,"studyType":23,"phases":164,"briefSummary":165,"conditions":166,"keywords":169,"overallStatus":172,"whyStopped":4,"lastUpdateSubmitDate":173,"lastUpdatePostDateStruct":174,"startDateStruct":176,"completionDateStruct":178,"leadSponsor":180,"locationsCount":41},"100650354","phase-2-glp-1-agonists-for-lung-function-improvement-and-muscle-restoration-in-copd-100650354","NCT07747805","GLP-1 Agonists for Lung Function Improvement and Muscle Restoration in COPD","GLIMR COPD: GLP-1 Agonists for Lung Function Improvement and Muscle Restoration in COPD","GLIMR COPD","Inclusion Criteria:\n\n* Age 40-80 years\n* Diagnosis of chronic obstructive pulmonary disease (COPD) with post-bronchodilator FEV₁\u002FFVC \\\u003C 0.70\n* GOLD stage 1-3 COPD (FEV₁ \\>30% predicted)\n* Former smoker with a smoking history of at least 10 pack-years\n* Body mass index (BMI) ≥27 kg\u002Fm² with at least one weight-related comorbidity (e.g., prediabetes, hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease) or BMI 30-40 kg\u002Fm²\n* Able and willing to provide written informed consent\n* Able to comply with study procedures and follow-up visits\n\nExclusion Criteria:\n\n* Type 2 diabetes mellitus (HbA1c \\> 6.5%)\n* Pregnancy or breastfeeding\n* Coagulopathy, defined as INR \\> 1.4 or platelet count \\\u003C80,000\u002FμL\n* Active malignancy, including lung cancer\n* Use of medications known to significantly alter muscle protein metabolism within 6 weeks of enrollment (e.g., oral corticosteroids, tamoxifen, high-dose estrogen, testosterone)\n* Personal or family history of medullary thyroid carcinoma\n* Multiple endocrine neoplasia syndrome type 2 (MEN2)\n* Known hypersensitivity or contraindication to tirzepatide or its components\n* History of pancreatitis\n* Severe gastrointestinal disease that, in the opinion of the investigator, would increase risk from study participation\n* Significant diabetic retinopathy\n* Clinically significant renal impairment\n* Clinically significant gallbladder disease\n* Current treatment with a DPP-4 inhibitor\n* COPD exacerbation within 60 days prior to enrollment\n* Participation in pulmonary rehabilitation within 2 weeks prior to enrollment\n* Any medical, psychiatric, or social condition that, in the opinion of the investigators, may interfere with study participation, adherence to study procedures, or participant safety",{"count":163,"type":22},30,[25],"Chronic obstructive pulmonary disease (COPD) is associated with systemic inflammation, obesity-related metabolic dysfunction, skeletal muscle impairment, and progressive decline in lung function. While obesity has historically been viewed as protective in COPD, emerging evidence suggests that excess adiposity and adipokine dysregulation, particularly elevated leptin levels, contribute to chronic inflammation, impaired muscle function, and worse clinical outcomes. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have demonstrated anti-inflammatory, metabolic, and potential muscle-preserving effects beyond weight loss, making them promising therapeutic candidates for COPD.\n\nThe GLIMR COPD study is a prospective, randomized, controlled pilot trial designed to evaluate the effects of tirzepatide on lung function, skeletal muscle health, inflammation, and body composition in overweight and obese adults with COPD. Thirty participants will be enrolled at the Cleveland Clinic COPD Center, including 20 participants receiving tirzepatide and 10 age- and sex-matched control participants. Study participants will be followed for 12 months with assessments performed at screening, baseline, 6 months, and 12 months. Tirzepatide-treated participants will undergo standard dose escalation to a maintenance dose of 2.4 mg weekly.\n\nThe primary objective is to determine the effect of GLP-1 receptor agonist therapy on skeletal muscle function and physiology over 12 months. Secondary objectives include evaluating changes in body composition, systemic inflammation, adipokine signaling, immune function, pulmonary physiology, physical performance, and treatment tolerability.\n\nThe study is built around three mechanistic aims. First, we will characterize the effects of GLP-1 therapy on systemic inflammation and immune dysregulation using longitudinal blood-based proteomic analyses and adipokine measurements, including leptin and adiponectin. Second, we will investigate the impact of GLP-1 therapy on skeletal muscle mitochondrial function and fatty acid oxidation using muscle biopsies obtained at baseline and 12 months, combined with high-resolution respirometry, transcriptomics, metabolomics, and proteomics. Third, we will assess changes in clinical outcomes including lung function, body composition, muscle strength, and physical performance.\n\nParticipants will undergo comprehensive phenotyping that includes spirometry, respiratory muscle strength testing, six-minute walk testing, handgrip strength, sit-to-stand testing, body composition assessment, diaphragm ultrasound, and non-contrast CT imaging of the lungs and thighs. Blood samples will be collected for biomarker, proteomic, metabolomic, genomic, and immunologic analyses. Vastus lateralis muscle biopsies will be performed at baseline and study completion to evaluate mitochondrial bioenergetics and molecular pathways associated with muscle remodeling.\n\nEligible participants will be adults aged 40-80 years with COPD, a smoking history of at least 10 pack-years, and overweight or obesity. Individuals with diabetes, active malignancy, recent COPD exacerbations, contraindications to tirzepatide, or conditions that could interfere with study participation will be excluded.\n\nThis pilot study is designed to generate critical mechanistic and clinical data regarding the role of GLP-1 receptor agonists in COPD. Findings will help define the relationships among obesity, adipokine signaling, systemic inflammation, skeletal muscle dysfunction, and lung disease progression, while providing preliminary efficacy estimates to support the design of a future multicenter randomized clinical trial evaluating GLP-1 therapy as a novel treatment strategy for COPD.",[28,167,168],"Obesity & Overweight","Sarcopenia",[28,170,171],"sarcopenia","obesity","NOT_YET_RECRUITING","2026-07-31",{"date":175,"type":33},"2026-08-05",{"date":177,"type":22},"2026-08-28",{"date":179,"type":22},"2029-08-15",{"name":181,"class":73},"The Cleveland Clinic",{"id":183,"slug":184,"hasResults":12,"nctId":185,"briefTitle":186,"officialTitle":187,"acronym":188,"eligibilityCriteria":189,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":190,"enrollmentInfo":191,"targetDuration":4,"studyType":23,"phases":193,"briefSummary":194,"conditions":195,"keywords":196,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":197,"lastUpdatePostDateStruct":198,"startDateStruct":200,"completionDateStruct":202,"leadSponsor":204,"locationsCount":207},"100624068","pep-buddy-in-pulmonary-rehabilitation-100624068","NCT07404826","PEP Buddy in Pulmonary Rehabilitation","A Randomized, Sham Controlled Clinical Trial to Assess the Effectiveness of a Positive End Expiratory Device for Accelerating and Maintaining Pulmonary Rehabilitation Gains","PEPR","Inclusion Criteria:\n\n* Veteran\n* Referral to Pulmonary Rehabilitation for COPD\n* FEV1 \\\u003C80% predicted\n* Participants must be able to exercise on 4L\u002Fm nasal cannula O2\n\nExclusion Criteria:\n\n* Those deemed by the study personnel to have a lung disease other than COPD impacting their daily dyspnea\n* Those that are unable to perform study procedures or are unwilling or unable to use PEP Buddy\n* Those that have a component of lung disease driven by aspiration or neurological conditions affecting the face or oropharynx\n* Those with a life expectancy of \\\u003C1 year\n* Those with a known surgical intervention that will require a prolonged recovery in the year after enrollment\n* Those with a malignancy beyond Stage I or non-melanoma skin cancer\n* Those shown shown to have memory loss of MOCA testing","89 Years",{"count":192,"type":22},120,[53],"In this study, the investigators will test Veterans with COPD in Pulmonary Rehabilitation. Between two groups, the investigators will give one group a device that assists with breathing and symptoms and the other receives a 'sham' device which does not provide these benefits. The investigators will test to see if the symptoms and exercise capacity of the group who receives this device improves faster in Pulmonary Rehabilitation and has longer lasting benefits after the end of Pulmonary Rehabilitation.",[28],[60],"2026-07-23",{"date":199,"type":33},"2026-07-24",{"date":201,"type":33},"2026-07-16",{"date":203,"type":22},"2030-07-29",{"name":205,"class":206},"VA Office of Research and Development","FED",2,{"id":209,"slug":210,"hasResults":12,"nctId":211,"briefTitle":212,"officialTitle":213,"acronym":214,"eligibilityCriteria":215,"healthyVolunteers":12,"sex":17,"minAge":83,"maxAge":216,"enrollmentInfo":217,"targetDuration":4,"studyType":23,"phases":219,"briefSummary":221,"conditions":222,"keywords":223,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":230,"startDateStruct":232,"completionDateStruct":234,"leadSponsor":236,"locationsCount":238},"100636477","phase-3-long-term-safety-and-tolerability-of-tozorakimab-in-patients-with-copd-and-history-of-exacerbations-100636477","NCT07566195","Long-term Safety and Tolerability of Tozorakimab in Patients With COPD and History of Exacerbations","A Phase III, Multicentre, Open-Label, Chronic Dosing, Extension Study to Evaluate the Long-term Safety of Tozorakimab in Participants With Chronic Obstructive Pulmonary Disease (COPD) With a History of COPD Exacerbations (ROMEO)","ROMEO","Inclusion Criteria:\n\n1. Participants previously randomized in predecessor studies.\n2. Participants should be affiliated with the French Social Security system.\n3. Participants who are willing to continue using contraceptive methods as agreed to for the predecessor studies.\n4. Capable of giving signed informed consent.\n\nExclusion Criteria:\n\n1. Clinically important pulmonary disease other than COPD.\n2. Participant meeting criteria for IP discontinuation as judged by the Investigator or the Sponsor.\n3. Current alcohol, drug or chemical abuse.\n4. Treatment with systemic corticosteroids or other immunosuppressive medication within 2 weeks prior to Visit 1 of ROMEO.\n5. Known history of:\n\n   1. Severe allergic reaction to any monoclonal and polyclonal antibody.\n   2. Allergy or reaction to any component of the IMP formulation.\n6. Receipt of blood products or immunoglobulins within 30 days prior to visit 1 of ROMEO.\n7. Receipt of live attenuated vaccines within 30 days prior to visit 1 of ROMEO.\n8. Chronic use (or expected need for chronic use during the study) of immunosuppressive medications (including, but not limited to, systemic corticosteroids), marketed or investigational biologic, or another prohibited medication.\n9. Chronic use of antibiotics if the duration of treatment is \\\u003C 3 months prior to Visit 1 of ROMEO (first IMP administration). Chronic macrolide or other antibiotic therapy is allowed provided the participant has been on a stable dose\u002Fregimen for ≥ 3 months prior to Visit 1 of ROMEO (first IMP administration) and has had at least one COPD exacerbation while on stable therapy.\n10. Use of allergen immunotherapy within 3 months of Visit 1 of ROMEO (first IMP administration), except for stable maintenance dose allergen-specific immunotherapy started 4 weeks prior to V1.\n11. Use of interferon gamma within 3 months of visit 1 of ROMEO (first IMP administration).\n12. Participation in any interventional clinical trial or receipt of any investigational non-biologic product within 30 days or 5 half-lives prior to Visit 1 of ROMEO (first IMP administration), whichever is longer.\n13. Involvement in the planning and\u002For conduct of the study (applies to both staff employed by the Sponsor and\u002For staff at the study site).\n14. Participants who are not able to comply with the study requirements, procedures, and restrictions.","99 Years",{"count":218,"type":22},59,[220],"PHASE3","ROMEO is a Phase III, multicentre, open-label, chronic-dosing extension study evaluating the long-term safety of two dose regimens of tozorakimab in participants with COPD and a history of exacerbations.\n\nEligible participants must have completed one of the predecessor studies.",[115,28],[224,225,115,28,226,227,228,229],"Tozorakimab","MEDI3506","Exacerbations","Safety","Biologic","Biologic Treatment",{"date":231,"type":33},"2026-07-21",{"date":233,"type":33},"2026-05-05",{"date":235,"type":22},"2028-12-29",{"name":237,"class":40},"AstraZeneca",13,{"id":240,"slug":241,"hasResults":12,"nctId":242,"briefTitle":243,"officialTitle":244,"acronym":245,"eligibilityCriteria":246,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":247,"targetDuration":4,"studyType":86,"phases":4,"briefSummary":249,"conditions":250,"keywords":251,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":259,"startDateStruct":261,"completionDateStruct":263,"leadSponsor":265,"locationsCount":267},"100588010","respiratory-muscles-in-end-stage-lung-disease-pathophysiological-processes--clinical-consequences-100588010","NCT06935825","Respiratory Muscles in End-stage Lung Disease: Pathophysiological Processes & Clinical Consequences","Respiratory Muscles in End-stage Lung Disease: PAthophysiological Processes & Clinical Consequences","Re-MAP","In order to be eligible to participate in this study, a participant must meet all of the following criteria:\n\n* Age \\> 18 years old\n* Severe COPD defined as COPD GOLD stage III or IV (FEV1 \\\u003C 50% of predicted; FEV1\u002FFVC ratio \\\u003C 70%, no significant reversibility, smoking history of at least 10 pack-years).\n* Being on the lung transplant waiting list\n* Being able to understand the patient information and provide written informed consent for participation in the study\n\nA potential participant who meets any of the following criteria will be excluded from participation in this study:\n\n* Patients suffering from acute conditions at the time of inclusion or LTx\n* Patients using more than 20 mg of morphine, or an equivalent, or more than 20 mg oxazepam, or an equivalent, at the time of inclusion or LTx",{"count":248,"type":22},60,"Rationale: In patients with chronic lung diseases, the role of respiratory muscle dysfunction has been underestimated. Also, current treatment options, like chronic NIV and lung transplantation (LTx), might also have deleterious effects on the respiratory muscles, and the mechanisms are poorly understood.\n\nTherefore in this exploratory study the objectives are to:\n\n1. Determine in vivo respiratory muscle function and progression of respiratory muscle dys-function in end-stage COPD patients\n2. Establish the correlation between changes in the structure and contractility of respiratory myofibers and in vivo respiratory muscle function.\n3. Establish the effect of chronic NIV on structure and contractility of respiratory muscle fi-bers\n4. Determine whether the structure and contractility of respiratory muscles cells at the time of LTx predicts clinical recovery post-LTx.\n\nStudy design: The study will be an exploratory observational cohort study following patients on the LTx waiting list during the waiting period and afterwards until they showed functional recovery of respiratory muscle function.\n\nStudy population: Adult COPD patients on the LTx waiting list will be included. Intervention (if applicable): None\n\nMain study parameters\u002Fendpoints:\n\nTo assess clinical functioning of the respiratory muscles we will assess respiratory electrical activity as a measure of respiratory effort by surface EMG, and thickening fraction of the diaphragm and intercostal muscles and diaphragm excursions by ultrasound and maximal in- and expiratory pressure to assess muscle output; all before and after LTx. We will relate and correct these data for hyperinflation and degree of lung damage by using data from standard care lung function tests and CT scans, and will relate these measurements to prior treatment (NIV settings) and outcome after LTx, by retrieving these data from the EPD.\n\nTo assess contractility of respiratory myofibers and in vivo respiratory muscle function, biopsies will be taken during LTx surgery and the biopsies will be analyzed in the lab of Prof. Ottenheijm (AmsterdamUMC) for individual myofiber functioning (strength, calcium sensitivity, myofiber characteristics) and in the lab of Dr. Pouwels for extracellular matrix characteristics.\n\nNature and extent of the burden and risks associated with participation, benefit and group relatedness:\n\nOverall, risks are believed to be minimal. The clinical measurements are non-invasive and\u002For regular performed in clinical practice. Also, we decided to do those measurements during regular control visits, limiting the burden for the patients. Taking biopsies from the respiratory muscles during surgery has been extensively performed without any risk; the biobank of the Ottenheijm group contains \\> 500 samples and never any complication has been observed. Also, in preparation of the present study we performed a pilot study in 12 COPD patients of whom.. biopsies were taken at the UMCG without side effects or complications. The biopsies will be done with the patients being under full anesthesia, so participants will feel no discomfort.",[28],[28,252,253,254,255,256,257,258],"NIV","Lung transplantation","Respiratory muscles","diaphragm","ultrasound","sEMG","MIP",{"date":260,"type":33},"2026-07-22",{"date":262,"type":33},"2025-09-01",{"date":264,"type":22},"2029-09-01",{"name":266,"class":73},"University Medical Center Groningen",4,{"id":269,"slug":270,"hasResults":12,"nctId":271,"briefTitle":272,"officialTitle":272,"acronym":4,"eligibilityCriteria":273,"healthyVolunteers":105,"sex":17,"minAge":83,"maxAge":274,"enrollmentInfo":275,"targetDuration":4,"studyType":23,"phases":277,"briefSummary":278,"conditions":279,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":280,"lastUpdatePostDateStruct":281,"startDateStruct":282,"completionDateStruct":284,"leadSponsor":286,"locationsCount":41},"100636606","phase-1-a-phase-i-study-to-evaluate-safety-tolerability-pharmacokinetics-and-pharmacodynamics-of-hrs-9821-powder-for-inhalation-administered-as-a-single-dose-in-healthy-participants-and-multiple-doses-in-patients-with-copd-100636606","NCT07567872","A Phase I Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HRS-9821 Powder for Inhalation Administered as a Single Dose in Healthy Participants and Multiple Doses in Patients With COPD","Inclusion Criteria:\n\n1. Informed consent was obtained to participate in the trial\n2. Body weight ≥45 kg,and BMI 18-33 kg\u002Fm2 (both ends included)\n3. The 12-lead ECG was normal or abnormal but clinically insignificant until randomization\n4. Contraception was strict from the time informed consent was signed until 1 month (for subjects receiving HRS-9821\u002F placebo) or 3 months (for male subjects receiving moxifloxacin) after the last dose\n5. All study regulations and procedures were followed and inhalation devices used in the study were used correctly during the study\n\n   The following inclusion criteria apply only to healthy subjects:\n6. Vital signs were normal at screening\n7. Pulmonary function was normal during screening\n8. No smoking or smoking cessation ≥12 months before screening, and previous smoking history \\\u003C5 pack-years；\n9. Healthy male 18-50 years old\n\n   The following inclusion criteria apply only to subjects with COPD\n10. Male or female, aged 40-75 years;\n11. Patients diagnosed with COPD;\n12. A post-bronchodilator FEV1 \u002FFVC \\\u003C 0.7,40% ≤FEV1 \\\u003C 80% of the predicted value,;\n13. Smoking history of≥ 10 pack-years;\n14. Normal chest X-ray examination results at screening;\n15. Supporting discontinuation of COPD-related medications before randomization；\n\nExclusion Criteria:\n\n1. Mean QTcF ≥ 450 ms at screening；\n2. Persons who had donated blood or had massive blood loss (\\> 400 ml) within 4 weeks before screening or who were interested in donating blood during the study\n3. Receipt of the investigational drug or device within 4 weeks before randomization or less than 5 times the half-life of the drug, whichever was greater;\n4. Patients who had difficulty in blood collection or could not tolerate venipuncture in the past, such as dizzy with needles or blood\n5. History of malignancy in any organ system\n6. Known allergies to salbutamol, study medication, or any excipients in the formulation\n7. Known previous infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV); Or positive HIV (according to a trial-site SOP), treponema pallidum antibody, HBV surface antigen, or HCV antibody before randomization\n8. History of alcohol abuse\n9. History of drug abuse and drug dependence in the past 5 years；\n10. Positive for alcohol or substance abuse test before randomization\n11. During the study, surgery or treatment that might interfere with the conduct of the study was planned；\n12. Unable or unwilling to fully adhere to the study protocol\n13. Mentally or legally incapacitated\n14. There were any other reasons for the subject not to participate in the study in the opinion of the investigator;\n15. Use of a strong\u002Fmoderate potency drug that inhibits or induces the hepatic drug-metabolizing enzyme CYP3A4 14 days before the first dose;\n16. Drugs with effects on P-glycoprotein (P-gp) or breast cancer resistance protein (BCRP) were anticipated to be used during the study;\n17. History of using HRS-9821 suspension;\n\n    The following exclusion criteria apply only to healthy subjects:\n18. Have been treated with antibiotics for upper and lower respiratory tract infections within 12 weeks prior to screening;\n19. Abnormal laboratory or physical examination results with clinical significance;\n20. Positive urine nicotine test before randomization;\n21. Have consumed a prescription within 14 days prior to the first dose or over-the-counter drugs within 48 h prior to the first dose;\n\nThe following exclusion criteria apply only to subjects with COPD 22. History of life-threatening acute exacerbation of COPD (AECOPD), including admission to intensive care unit and\u002For need for invasive ventilator support; 23. Diagnosed with other respiratory disorders; 24. Pulmonary heart disease, or pulmonary hypertension caused by lung disease and\u002For hypoxia; 25. History of lung volume reduction surgery, partial lung resection, lung transplantation, and other surgeries that may affect pulmonary function results; 26. History of AECOPD requiring systemic glucocorticoids or antibiotics or hospitalization within 4 weeks prior to screening; 27. Lower respiratory tract infection requiring antibiotic treatment within 4 weeks prior to screening; 28. Requiring oxygen therapy or home non-invasive ventilation; 29. Currently using or plan to use non-selective beta blockers or other drugs with bronchoconstrictive effects during the study; 30. Patients with serious trauma or major surgery within 6 months prior to screening who are still in the recovery period; 31. Abnormal laboratory tests at screening and baseline.","75 Years",{"count":276,"type":22},48,[109],"The aim of this study was to evaluate the safety and tolerability of HRS-9821 Powder for Inhalation administered in a single dose in healthy individuals and multiple doses in patients with COPD。",[28],"2026-07-17",{"date":35,"type":33},{"date":283,"type":33},"2026-07-09",{"date":285,"type":22},"2026-09",{"name":39,"class":40},{"id":288,"slug":289,"hasResults":12,"nctId":290,"briefTitle":291,"officialTitle":291,"acronym":292,"eligibilityCriteria":293,"healthyVolunteers":12,"sex":17,"minAge":83,"maxAge":4,"enrollmentInfo":294,"targetDuration":4,"studyType":23,"phases":295,"briefSummary":296,"conditions":297,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":300,"lastUpdatePostDateStruct":301,"startDateStruct":302,"completionDateStruct":304,"leadSponsor":306,"locationsCount":41},"100647384","identification-of-diagnostic-and-prognostic-biomarkers-in-the-pathological-continuum-of-bronco-chronic-obstructive-pulmonary-disease-idiopathic-pulmonary-fibrosis-and-pulmonary-neoplasia-100647384","NCT07707245","Identification of Diagnostic and Prognostic Biomarkers in the Pathological Continuum of Bronco Chronic Obstructive Pulmonary Disease, Idiopathic Pulmonary Fibrosis and Pulmonary Neoplasia","RESPIRO","Inclusion Criteria:\n\n* Age ≥ 18 years.\n* Clinical diagnosis of: Chronic Obstructive Pulmonary Disease (COPD), current or former smokers; and\u002For Idiopathic Pulmonary Fibrosis (IPF), current or former smokers; and\u002For Resectable lung adenocarcinoma (Stage I-III, according to clinical indication for surgical resection).\n* Ability to comply with study procedures and follow-up visits.\n\nExclusion Criteria:\n\n* Inability or unwillingness to provide informed consent.\n* Active respiratory infection or acute exacerbation of COPD or IPF at the time of enrollment.\n* Previous or concomitant malignant disease (except non-melanoma skin cancer) that could interfere with study objectives.\n* Prior systemic immunosuppressive or anti-inflammatory therapy that may significantly alter immune profiling within a defined washout period (if applicable per protocol).\n* Severe comorbid conditions limiting life expectancy or ability to complete follow-up (e.g., advanced heart failure, severe renal or hepatic disease).\n\nInadequate biological sample quality or impossibility to obtain required blood samples.",{"count":192,"type":22},[53],"Primary Objective:\n\nTo evaluate the association between inflammatory, immunological, genetic, and epigenetic biomarkers measured at enrollment and the clinical, functional, and phenotypic characteristics of patients with chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF), and lung cancer.\n\nSecondary Objective:\n\nTo assess the prognostic value of the identified biomarkers by evaluating their ability to predict clinical outcomes at 12 months.\n\nPrimary Outcome Measure:\n\nAssociation between baseline inflammatory, immunological, genetic, and epigenetic biomarkers and disease-specific clinical, functional, and phenotypic characteristics assessed at enrollment, including:\n\nCOPD: current or former smokers, stratified according to the predominant phenotype (emphysema or bronchiolitis); IPF: rapid progressors, slow progressors, and patients with combined pulmonary fibrosis and emphysema (CPFE); Lung cancer: current smokers, former smokers who quit less than 15 years before enrollment, former smokers who quit 15 years or more before enrollment, and never-smokers.\n\nSecondary Outcome Measure:\n\nPredictive performance of baseline inflammatory, immunological, genetic, and epigenetic biomarkers for 12-month clinical outcomes.",[28,298,299],"Idiopathic Pulmonary Fibrosis (IPF)","Lung Cancer","2026-07-15",{"date":201,"type":33},{"date":303,"type":33},"2026-04-22",{"date":305,"type":22},"2028-10-30",{"name":307,"class":73},"Fondazione Don Carlo Gnocchi ETS",{"id":309,"slug":310,"hasResults":12,"nctId":311,"briefTitle":312,"officialTitle":313,"acronym":314,"eligibilityCriteria":315,"healthyVolunteers":12,"sex":17,"minAge":83,"maxAge":316,"enrollmentInfo":317,"targetDuration":4,"studyType":23,"phases":319,"briefSummary":320,"conditions":321,"keywords":323,"overallStatus":172,"whyStopped":4,"lastUpdateSubmitDate":328,"lastUpdatePostDateStruct":329,"startDateStruct":330,"completionDateStruct":332,"leadSponsor":334,"locationsCount":41},"100647317","evaluating-customized-antibiotic-duration-cda-strategy-in-acute-exacerbations-of-copd-100647317","NCT07708337","Evaluating Customized Antibiotic Duration (CDA) Strategy in Acute Exacerbations of COPD","Evaluating Customized Antibiotic Duration (CDA) Strategy in Acute Exacerbations of COPD: Protocol for Randomized Controlled Trial","CDA","Inclusion Criteria:\n\n* Adults aged 18 years or older\n* Physician-diagnosed COPD, confirmed by post-bronchodilator spirometry (FEV1\u002FFVC \\\u003C 0.70) where available, or by documented prior spirometry consistent with COPD\n* Current acute exacerbation of COPD requiring antibiotic therapy in the judgment of the treating physician, with at least two cardinal symptoms (increased dyspnoea, sputum volume, or sputum purulence)\n* Able and willing to provide written informed consent and to comply with study procedures and follow-up\n\nExclusion Criteria:\n\n* Documented infection requiring a defined prolonged antibiotic course (e.g. pneumonia with complications, bronchiectasis exacerbation, lung abscess, empyema)\n* Need for immediate intensive care admission or invasive mechanical ventilation at presentation\n* Severe immunosuppression (e.g. neutropenia, active malignancy on chemotherapy, organ transplantation, advanced HIV)\n* Suspected or confirmed pulmonary tuberculosis or another respiratory infection requiring a different antimicrobial approach\n* Pregnancy or breastfeeding\n* Prior enrolment in this trial or current participation in another interventional AECOPD trial.","90 Years",{"count":318,"type":22},502,[53],"Introduction Acute exacerbations of chronic obstructive pulmonary disease (AECOPD) are a major source of morbidity, mortality and antibiotic consumption worldwide. Although international guidance now recommends short antibiotic courses for AECOPD, prescribing in many tertiary hospitals in Pakistan is neither standardised nor guideline-concordant, and prolonged courses remain common. Reducing unnecessary antibiotic exposure is a recognised strategy to contain antimicrobial resistance (AMR), but locally generated evidence on the safety and efficacy of shorter courses is lacking.\n\nMethod and analysis This multicentre, prospective, parallel-group, open-label, randomised controlled non-inferiority trial will compare a 7-day antibiotic regimen (experimental) with the locally conventional 14-day regimen (active control) in adults hospitalised with AECOPD requiring antibiotics. Participants will be randomised 1:1 with allocation stratified by site. The primary outcome is clinical success at Day 30 after randomisation, defined as resolution or substantial improvement of baseline exacerbation symptoms without need for additional systemic antibiotics, major treatment modification, or readmission for treatment failure. Assuming 80% clinical success in both arms, a non-inferiority margin of 7-or8 percentage points, one-sided α = 0.025 and 80% power, 251 participants per arm are required; allowing for 10% attrition, the target is 558 participants (279 per arm). The primary analysis will estimate the between-group risk difference with its two-sided 95% confidence interval in both the intention-to-treat and per-protocol populations; non-inferiority will be concluded if the lower confidence limit lies above 10 percentage points in both populations. Secondary outcomes include time to symptom resolution, antibiotic-related adverse events, treatment failure, relapse, rehospitalisation, all-cause mortality and antibiotic consumption.\n\nEthics and dissemination The ethical approval has been obtained from the Institutional Review Board of the hospital (IRB-113-07-08-25). The outcomes and findings will be disseminated through peer-reviewed journal articles and will engage policymakers on various forums, including clinical settings.\n\nDiscussion The optimal duration of antibiotic therapy for AECOPD remains uncertain. Shorter treatment courses may reduce antibiotic exposure, adverse events, and the development of AMR. This trial will compare the effectiveness and safety of 7-day and 14-day antibiotic regimens in patients with AECOPD. The findings may help inform clinical guidelines and promote more appropriate antibiotic use.",[28,322],"Acute Exacerbation of COPD",[28,324,325,326,327],"ACOPD","Antibiotic duration","Pakistan","ICU","2026-07-14",{"date":201,"type":33},{"date":331,"type":22},"2026-08-01",{"date":333,"type":22},"2027-02-28",{"name":335,"class":73},"Capital Development Authority (CDA) Hospital Islamabad",{"id":337,"slug":338,"hasResults":12,"nctId":339,"briefTitle":340,"officialTitle":341,"acronym":4,"eligibilityCriteria":342,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":343,"targetDuration":4,"studyType":23,"phases":345,"briefSummary":346,"conditions":347,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":348,"lastUpdatePostDateStruct":349,"startDateStruct":350,"completionDateStruct":352,"leadSponsor":354,"locationsCount":41},"100647500","continuous-versus-high-intensity-interval-exercise-in-chronic-obstructive-pulmonary-disease-100647500","NCT07707271","Continuous Versus High Intensity Interval Exercise in Chronic Obstructive Pulmonary Disease","Changes in Brain Oxygenation, Cadiopulmonary Parameters and Autonomic Nervous System Function During Moderate Intensity Continuous Versus High Intensity Interval Exercise in Chronic Obstructive Pulmonary Disease","Inclusion Criteria:\n\n* Clinical diagnosis of COPD based on smoking history (pack\u002Fyears) or exposure to other risk factors and post bronchodilation forced expiratory volume (FEV1) to forced vital capacity (FVC) ratio \\\u003C0.7\n* Resting arterial oxygen partial pressure at room air \\>60 mmHg, according to recent (within a week) arterial blood gases assessment\n* Disease being stable and treated optimal, based on current GOLD guidelines.\n* Provision of informed written signed consent prior to study entry\n\nExclusion Criteria:\n\n* Recent respiratory infection or exacerbation (as indicated by deterioration of respiratory symptoms, hospital admission and\u002For change in medication within the previous month), within the past 3 months\n* Changes in COPD medication with the past month\n* History of asthma and\u002For reversible airway obstruction (post bronchodilation FEV1\u002F FVC \\>0.7)\n* Pulmonary hypertension\n* Congestive heart failure (Left Ventricle Ejection Fraction \\\u003C50% in recent echocardiography)\n* Severe peripheral artery disease\n* Chronic Kidney disease with eGFR \\\u003C 30 ml\u002Fmin (KDIGO stages 3b, 4 ,5)\n* Active acute or chronic infectious diseases\n* Active malignant disease or hematologic disorder under treatment\n* History of neuromuscular disorder\n* History of severe intellectual disability or mental disorder\n* Any contradiction to moderate-high intensity exercise or cardiopulmonary exercise testing according to ATS\u002FACCP guidelines, such as: myocardial infarction within the past 6 months, unstable angina, syncope, symptomatic severe aortic stenosis, uncontrolled arrhythmias causing symptoms or hemodynamic compromise, acute pulmonary embolus or pulmonary infarction, thrombosis of lower extremities, suspected dissecting aneurysm, pulmonary edema, severe untreated arterial hypertension at rest (\\> 200 mm Hg systolic, \\> 120 mm Hg diastolic blood pressure), orthopedic impairment that compromises exercise performance.",{"count":344,"type":22},12,[53],"Chronic Obstructive Pulmonary Disease (COPD) is characterized by exercise intolerance, which is a prognostic factor of disease severity and mortality and is usually attributed to ventilatory limitations. Emerging evidence indicates that cerebral oxygenation may also be an important contributor, being impaired both at rest and during exercise in COPD patients. Furthermore, abnormal systemic hemodynamic responses and autonomic nervous system (ANS) dysfunction have been observed, which may further impair cerebral oxygenation. The type of exercise training applied in pulmonary rehabilitation (continuous versus interval) appears to influence these mechanisms differently, yet evidence on their impact on cerebral oxygenation in COPD remains scarce. The aim of this study is to compare, for the first time, the acute changes in cerebral oxygenation, CPET parameters, systemic hemodynamic responses, and autonomic responses in patients with COPD who undergo a high-intensity interval aerobic exercise (HIIE) protocol versus a moderate-intensity continuous aerobic exercise (MICE) protocol. These findings will have important clinical implications, as they may guide the choice of the most appropriate exercise modality in pulmonary rehabilitation.",[28],"2026-07-11",{"date":201,"type":33},{"date":351,"type":22},"2026-06",{"date":353,"type":22},"2028-07",{"name":355,"class":73},"George Papanicolaou Hospital",{"id":357,"slug":358,"hasResults":12,"nctId":359,"briefTitle":360,"officialTitle":360,"acronym":361,"eligibilityCriteria":362,"healthyVolunteers":12,"sex":17,"minAge":83,"maxAge":4,"enrollmentInfo":363,"targetDuration":4,"studyType":86,"phases":4,"briefSummary":365,"conditions":366,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":283,"lastUpdatePostDateStruct":373,"startDateStruct":375,"completionDateStruct":377,"leadSponsor":379,"locationsCount":381},"100453229","collection-of-blood-from-healthy-patients-patients-with-benign-disease-and-patients-with-cancer-100453229","NCT05181826","Collection of Blood From Healthy Patients, Patients With Benign Disease and Patients With Cancer","ELITE","Inclusion Criteria:\n\n2.1.1 Age 18 years or older.\n\n2.1.2 A diagnosis of cancer, cancer remission, benign disease (benign tumor, diabetes, liver cirrhosis, chronic hepatitis B or hepatitis C virus infection, Chronic obstructive pulmonary disease, etc.) or apparently healthy volunteers. .\n\nExclusion Criteria:\n\n2.2.1 Patients that are unwilling or unable to sign the Informed Consent Form will be excluded.\n\n2.2.2 Approximately 50 mL of blood will be drawn from participants within an 8-week period under this protocol. Patients that have already given 50 mL of blood within this time frame will be excluded.",{"count":364,"type":22},1200,"To acquire blood samples from subjects for various purposes, including: i) determining the sensitivity and specificity of select DNA methylation markers for the detection of various types of cancer, ii) identifying benign conditions that may induce false positive or false negative results, and iii) defining the effects of potential interfering substances, such as chemotherapy drugs.",[367,368,369,370,371,372,28],"Cancer","Liver Cirrhosis","Chronic Hepatitis","Hepatitis B","Hepatitis C","Diabetes",{"date":374,"type":33},"2026-07-10",{"date":376,"type":33},"2019-05-21",{"date":378,"type":22},"2028-01",{"name":380,"class":40},"Helio Genomics",7,{"id":383,"slug":384,"hasResults":12,"nctId":385,"briefTitle":386,"officialTitle":387,"acronym":388,"eligibilityCriteria":389,"healthyVolunteers":12,"sex":17,"minAge":390,"maxAge":4,"enrollmentInfo":391,"targetDuration":4,"studyType":23,"phases":392,"briefSummary":393,"conditions":394,"keywords":398,"overallStatus":172,"whyStopped":4,"lastUpdateSubmitDate":401,"lastUpdatePostDateStruct":402,"startDateStruct":403,"completionDateStruct":404,"leadSponsor":406,"locationsCount":4},"100645437","effects-of-adapted-snacktivity-intervention-on-cognition-and-self-care-in-copd-patients-100645437","NCT07702994","Effects of Adapted Snacktivity™ Intervention on Cognition and Self-Care in COPD Patients","Development and Evaluation of a Culturally Adapted Snacktivity™ Intervention to Enhance Cognition and Self-Care in Patients With Chronic Obstructive Pulmonary Disease (COPD)","Snacktivity™","* Inclusion Criteria:\n\n  1. Confirmed diagnosis of COPD in accordance with the 2026 Global Initiative for Chronic Obstructive Lung Disease (GOLD) Guideline, with a post-bronchodilator ratio of FEV₁\u002FFVC \\\u003C 70%;\n  2. Aged ≥ 60 years;\n  3. Clinically stable condition;\n  4. Score at or below the age- and education-adjusted cutoff (16th percentile) on the Hong Kong Montreal Cognitive Assessment (HK-MoCA) 5-minute Protocol, indicating mild cognitive impairment;\n  5. No exercise contraindications;\n  6. No active wrist skin conditions that would prevent wearing an activity tracker (Phase 2 \\& 3);\n  7. Willingness to wear an activity tracker during the intervention (Phase 2 \\& 3);\n  8. Possession of a smartphone capable of receiving instant messages (Phase 2 \\& 3);\n  9. Proficiency in Cantonese or Mandarin;\n  10. Willingness to provide written informed consent and commitment to trial completion.\n* Exclusion Criteria\n\n  1. Receipt of oxygen therapy for ≥ 15 hours per day or requirement for mechanical ventilation;\n  2. History of brain injury or stroke;\n  3. Presence of severe comorbidities including coronary artery disease, severe hepatic or renal dysfunction;\n  4. Diagnosis of psychiatric disorders, deafness, severely limited physical mobility, or inability to cooperate with trial interventions;\n  5. For Phase 2 and Phase 3: Use of medications documented to impact cognitive function.","60 Years",{"count":5,"type":22},[53],"This clinical trial aims to evaluate whether a culturally adapted Snacktivity™ program can improve cognitive function and self-care abilities in patients with Chronic Obstructive Pulmonary Disease (COPD) in Hong Kong.\n\nThe main questions it aims to answer are:\n\n1. Does the Snacktivity™ program improve the cognitive function of participants (including both global cognition and targeted subdomains)?\n2. Does the program improve participants' self-care abilities?\n\nThe study consists of three sequential phases:\n\nPhase 1 (Co-design workshops): Co-design workshops will be conducted with COPD patients, healthcare professionals (nurses, physical therapists, occupational therapists), and family caregivers to culturally adapt the Snacktivity™ program for Hong Kong COPD patients.\n\nPhase 2 (Feasibility Pilot RCT): The adapted program will be tested in a small-scale pilot study to assess its feasibility and short-term clinical effects.\n\nPhase 3 (Full-scale RCT): A full-scale randomised controlled trial will be conducted to evaluate the program's efficacy on the primary and secondary outcomes.\n\nParticipants in the intervention group will be asked to:\n\nParticipate in the culturally adapted Snacktivity™ program that integrates short, manageable \"snacks\" of physical activity into daily routines.\n\nWear an activity tracker to monitor physical activity levels. Complete questionnaires at multiple time points assessing cognitive function, self-care abilities, physical activity levels, self-efficacy, exercise capacity, quality of life, anxiety, and depression.\n\nResearchers will compare the intervention group to an attention control group (receiving usual care with health education) to see if the Snacktivity™ program leads to greater improvements in these outcomes.",[28,395,396,397],"Physical Activity","Cognition","Self Care",[28,399,400],"cognitive function","self care","2026-07-08",{"date":328,"type":33},{"date":300,"type":22},{"date":405,"type":22},"2028-06-30",{"name":407,"class":73},"The University of Hong Kong",{"id":409,"slug":410,"hasResults":12,"nctId":411,"briefTitle":412,"officialTitle":413,"acronym":414,"eligibilityCriteria":415,"healthyVolunteers":105,"sex":17,"minAge":83,"maxAge":316,"enrollmentInfo":416,"targetDuration":4,"studyType":23,"phases":418,"briefSummary":419,"conditions":420,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":421,"lastUpdatePostDateStruct":422,"startDateStruct":424,"completionDateStruct":426,"leadSponsor":428,"locationsCount":41},"100451830","the-acute-cardiorespiratory-response-to-blood-flow-restricted-versus-traditional-exercise-training-regimens-care-bfr-100451830","NCT05163600","The Acute Cardiorespiratory Response to Blood-flow Restricted Versus Traditional Exercise Training Regimens (CaRe BFR)","The Acute Cardiorespiratory Response to Blood-flow Restricted Versus Traditional Exercise Training Regimens (CaRe BFR):4 Randomized Crossover Studies","CaRe-BFR","Inclusion and exclusion for the healthy participants are defined by the following criteria.\n\nInclusion criteria:\n\n* Age ≥ 18 years\n* Clinically healthy\n\nExclusion criteria:\n\n* Physical or intellectual impairment precluding informed consent or protocol adherence\n* Non-German speaking (precluding informed consent)\n* Pain during exercise of any origin\n* Pregnancy\n* History of thromboembolic event in the lower extremity\n* Resting systolic blood pressure \\\u003C100 mmHg\n\nInclusion and exclusion for the COPD participants are defined by the following criteria.\n\nInclusion criteria:\n\n* Age ≥ 18 years\n* Diagnosed COPD according to GOLD-guidelines12\n\nExclusion criteria:\n\n* Physical or intellectual impairment precluding informed consent or protocol adherence\n* Non-German speaking (precluding informed consent)\n* Acute or recent (within the last 6 weeks) exacerbation of COPD\n* Pain during exercise of any origin\n* Pregnancy\n* History of thromboembolic event in the lower extremity\n* Resting systolic blood pressure \\\u003C100 mmHg",{"count":417,"type":22},24,[53],"The investigators hypothesize that BFR exercise regimens result in a different acute cardiorespiratory response pattern compared to traditional exercise regimens. Furthermore, the investigators hypothesize that these patterns differ between healthy participants and participants with COPD.\n\nRegarding secondary objective, the investigators hypothesize that BFR results in lower blood pressure responses compared to traditional exercise training in both healthy and COPD participants.",[28],"2026-07-03",{"date":423,"type":33},"2026-07-07",{"date":425,"type":33},"2022-05-20",{"date":427,"type":22},"2026-12-31",{"name":429,"class":73},"University of Zurich",{"id":431,"slug":432,"hasResults":12,"nctId":433,"briefTitle":434,"officialTitle":435,"acronym":4,"eligibilityCriteria":436,"healthyVolunteers":105,"sex":17,"minAge":83,"maxAge":274,"enrollmentInfo":437,"targetDuration":4,"studyType":23,"phases":439,"briefSummary":440,"conditions":441,"keywords":442,"overallStatus":172,"whyStopped":4,"lastUpdateSubmitDate":446,"lastUpdatePostDateStruct":447,"startDateStruct":448,"completionDateStruct":450,"leadSponsor":452,"locationsCount":4},"100646731","feasibility-of-noninvasive-trigeminal-nerve-stimulation-during-exercise-100646731","NCT07686302","Feasibility of Noninvasive Trigeminal Nerve Stimulation During Exercise","Noninvasive Trigeminal Nerve Stimulation for Dyspnea: Mechanistic Characterization in Healthy Volunteers and Feasibility in COPD","Arm1 - Healthy Volunteers\n\nInclusion Criteria:\n\n* Adults aged 18-50 years\n* BMI 18-30 kg\u002Fm²\n* Ability to provide informed consent and complete study procedures in English\n\nExclusion Criteria:\n\n* Current daytime respiratory impairment such as uncontrolled asthma, uncontrolled COPD, pneumonia, or interstitial lung disease\n* Use of supplemental oxygen\n* Pregnancy or breastfeeding\n* Current use of acetazolamide, Sodium-glucose cotransporter-2 (SGLT2) inhibitors, or daily opioids\n* History of claustrophobia or panic disorder\n* Metallic implants in the craniofacial or cervical region that may interfere with electrode placement or electrical stimulation\n* Implanted cardiac or neuroelectric device (e.g., pacemaker, implantable cardioverter-defibrillator (ICD), deep brain stimulator, vagus nerve stimulator, implanted drug pump)\n* Open, broken, inflamed, infected, or healing skin lesions at or near facial electrode placement sites\n* Resting heart rate \\\u003C60 Beats Per Minute\n* History of seizure disorder or epilepsy\n\nArm 2 -COPD\n\nInclusion Criteria:\n\n* Adults aged 40-75 years\n* Confirmed diagnosis of COPD by spirometry (post-bronchodilator Forced Expiratory Volume (FEV1) \u002FForced Vital Capacity (FVC) \\\u003C0.70) or provider documentation in medical records\n* Modified Medical Research Council (mMRC) dyspnea grade ≥2\n* Stable COPD (no exacerbation requiring hospitalization, systemic corticosteroids, or antibiotic therapy within the preceding 6 weeks)\n* On stable COPD therapy for at least 4 weeks prior to enrollment\n* Ability to provide informed consent and complete questionnaires in English\n* Resting Peripheral Capillary Oxygen Saturation (SpO₂) ≥88% on room air or prescribed supplemental oxygen\n\nExclusion Criteria:\n\n* Unstable cardiovascular disease (e.g., unstable angina, decompensated heart failure, recent MI within 6 months, uncontrolled arrhythmia) or peripheral vascular disease\n* Patients with cardiovascular disease, including chest pain, heart failure, and aortic stenosis\n* Resting heart rate \\\u003C60 BPM\n* Implanted cardiac or neuroelectric device (e.g., pacemaker, ICD, deep brain stimulator, vagus nerve stimulator, implanted drug pump)\n* Metallic implants in the craniofacial or cervical region that may interfere with electrode placement or stimulation\n* Open, broken, inflamed, infected, or healing skin lesions at or near facial electrode placement sites\n* Active trigeminal neuralgia or other cranial neuropathy\n* History of seizure disorder or epilepsy\n* Severe or uncontrolled psychiatric disorder (e.g., psychosis, severe untreated anxiety or panic disorder) that would impair the ability to participate\n* Pregnancy or breastfeeding\n* COPD exacerbation requiring hospitalization, systemic corticosteroids, or antibiotics within the preceding 3 months\n* Musculoskeletal pain, injury, or any other condition that precludes the use of a stationary bike for Cardiopulmonary Exercise Test (CPET)\n* Any condition that, in the opinion of the investigator, would compromise participant safety or data integrity",{"count":438,"type":22},40,[53],"The purpose of this study is to examine 1) effects of cutaneous electrical trigeminal nerve stimulation (eTNS) on respiratory control in healthy volunteers and 2) explore the potential of this approach to mitigate dyspnea in patients with chronic obstructive lung disease (COPD).",[28],[443,444,445],"dyspnea","Control of breathing","neural stimulation","2026-06-30",{"date":423,"type":33},{"date":449,"type":22},"2026-10-01",{"date":451,"type":22},"2027-09-30",{"name":453,"class":73},"Johns Hopkins University",{"id":455,"slug":456,"hasResults":12,"nctId":457,"briefTitle":458,"officialTitle":459,"acronym":4,"eligibilityCriteria":460,"healthyVolunteers":12,"sex":17,"minAge":83,"maxAge":19,"enrollmentInfo":461,"targetDuration":4,"studyType":23,"phases":463,"briefSummary":464,"conditions":465,"keywords":4,"overallStatus":172,"whyStopped":4,"lastUpdateSubmitDate":466,"lastUpdatePostDateStruct":467,"startDateStruct":469,"completionDateStruct":471,"leadSponsor":472,"locationsCount":4},"100646865","effect-of-oral-astaxanthin-formula-on-pulmonary-rehabilitation-in-patients-with-copd-100646865","NCT07684391","Effect of Oral Astaxanthin Formula on Pulmonary Rehabilitation in Patients With COPD","Effect of Oral Astaxanthin Formula Supplement on Pulmonary Rehabilitation in Patients With Chronic Obstructive Pulmonary Disease: a Multicenter, Randomized Controlled Study","Inclusion Criteria:\n\n* Patients who met the GOLD diagnostic criteria for stage II-IV COPD\n* Patients who met the indications for pulmonary rehabilitation training: mMRC score\n\n  * 3 or self-reported decline in physical function.\n\nExclusion Criteria:\n\n* Hypoxemia (resting partial pressure of oxygen \\\u003C 60mmHg or oxygen saturation \\\u003C 88%) or patients requiring continuous oxygen therapy or with any contraindications to exercise testing (refer to the American Society of Thoracic Surgeons\u002FAmerican College of Chest Physicians exercise testing guidelines).\n* Using oral glucocorticoids\n* Long-term oxygen therapy\n* Participated in a supervised exercise program within the past 12 months\n* History of other pulmonary diseases, including pneumoconiosis, bronchiectasis, tuberculosis, primary pulmonary hypertension, pulmonary embolism, interstitial lung disease\n* Skeletal, neuromuscular, cardiovascular, or metabolic disorders that limit the participant's ability to exercise actively or that involve muscle activity, such as cancer, diabetes, muscle weakness, etc.",{"count":462,"type":22},140,[53],"The goal of this clinical trial is to investigate whether an astaxanthin-based dietary supplement combined with a pulmonary rehabilitation training program could improve exercise capacity in patients with COPD. The main questions it aims to answer are:\n\n• whether an astaxanthin-based dietary supplement combined with a pulmonary rehabilitation training program could improve 6MWD in patients with COPD.\n\nThe drug administration group will receive:\n\n* Two capsules of astaxanthin formula supplement daily for 8 weeks.\n* Pulmonary rehabilitation training: a total of 8 weeks, 2-3 times a week.\n\nThe control group will receive a total of 8-week pulmonary rehabilitation training, 2-3 times a week.\n\nThe investigators will compare the drug administration group and the control group to see if the difference between the 2 groups reaches a minimal clinically important difference.",[28],"2026-06-29",{"date":468,"type":33},"2026-07-06",{"date":470,"type":22},"2026-07-01",{"date":427,"type":22},{"name":473,"class":73},"China-Japan Friendship Hospital",{"id":475,"slug":476,"hasResults":12,"nctId":477,"briefTitle":478,"officialTitle":478,"acronym":4,"eligibilityCriteria":479,"healthyVolunteers":12,"sex":17,"minAge":83,"maxAge":480,"enrollmentInfo":481,"targetDuration":4,"studyType":86,"phases":4,"briefSummary":483,"conditions":484,"keywords":488,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":491,"lastUpdatePostDateStruct":492,"startDateStruct":493,"completionDateStruct":494,"leadSponsor":496,"locationsCount":41},"100591807","evaluation-of-ventilation-defects-downstream-of-mucus-plugs-in-patients-with-muco-obstructive-lung-disease-100591807","NCT06985225","Evaluation of Ventilation Defects Downstream of Mucus Plugs in Patients With Muco-Obstructive Lung Disease","Inclusion Criteria:\n\n* Adequate completion of informed consent process with written documentation\n* Patients 18 - 65 years old\n* • Physician diagnosis of muco-obstructive pulmonary disease, including cystic fibrosis, severe asthma, chronic obstructive pulmonary disease, or non-cystic fibrosis bronchiectasis for \\> 1 year\n* Able to perform reproducible spirometry according to ATS criteria based on clinical PFTs.\n\nExclusion Criteria:\n\n* Respiratory tract infection within the 4 weeks prior to Visit 1\n* Body mass index (BMI) \\> 30 at Visit 1\n* One-time doses such as intra-articular injections require a 4-week washout prior to Visit 1\n* ER visit related to pulmonary condition within the previous 4 weeks of Visit 1\n* Significant concomitant medical illness, including (but not limited to) heart disease, cancer, uncontrolled diabetes, other chronic lung diseases (determined by the Investigator.)\n* Resting O2 saturation \\\u003C90% with maximum supplemental O2 delivered by nasal canula\n* Positive urine pregnancy test\n* Participation in an intervention study (including bronchoscopy) or use of investigative drugs within the past 30 days or plans to enroll in such a trial during the study\n* Unable or unlikely to complete study assessments in the opinion of the Investigator\n* Study intervention poses undue risk to patient in the opinion of the Investigator\n* Conditions that will prohibit MRI scanning determined by the MRI safety screening.","65 Years",{"count":482,"type":22},8,"In this study, xenon MRI will be used to evaluate regional functional consequences of mucus plugs in the lungs of patients with muco-obstructive pulmonary disease. Mucus plugs will be identified using CT imaging, and xenon MRI will be used to evaluate ventilation and gas exchange impairments in regions of the lungs corresponding to the airways downstream of mucus plugs.",[485,28,486,487],"Severe Asthma","Non-CF Bronchiectasis","Cystic Fibrosis (CF)",[489,490,485,28,486],"Xenon MRI","Mucus Plug","2026-06-26",{"date":470,"type":33},{"date":149,"type":33},{"date":495,"type":22},"2026-12",{"name":497,"class":73},"University of Kansas Medical Center",{"id":499,"slug":500,"hasResults":12,"nctId":501,"briefTitle":502,"officialTitle":503,"acronym":4,"eligibilityCriteria":504,"healthyVolunteers":105,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":505,"targetDuration":4,"studyType":86,"phases":4,"briefSummary":507,"conditions":508,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":511,"lastUpdatePostDateStruct":512,"startDateStruct":514,"completionDateStruct":516,"leadSponsor":518,"locationsCount":41},"100554340","health-literacy-physical-and-cognitive-function-health-related-behaviors-and-quality-of-life-in-copd-100554340","NCT06497816","Health Literacy, Physical and Cognitive Function, Health-related Behaviors, and Quality of Life in COPD","An Investigation of Health Literacy, Physical and Cognitive Function, Health-related Behaviors, and Quality of Life in Chronic Obstructive Pulmonary Disease and Healthy Individuals","Inclusion criteria for the COPD group:\n\n* Being over 40 years old,\n* Diagnosed with COPD and being clinically stable,\n* Being able to cooperate with the tests to be performed,\n* Not having any cardiovascular disease, orthopedic or neurological problems that may affect the tests,\n* Being willing to participate in the study.\n\nExclusion criteria for the COPD group:\n\n* Being in an acute exacerbation period,\n* Having any cardiovascular disease, orthopedic or neurological problems that may affect the tests,\n* Not being willing to participate in the study.\n\nInclusion criteria for the control group:\n\n* Being willing to participate in the study and being over 40 years old\n* Not having any known disease\n\nExclusion criteria for the control group:\n\n* Not being able to cooperate with the tests to be performed\n* Not being willing to participate in the study",{"count":506,"type":22},144,"Health literacy is important for controlling disease progression and living a healthy life with illness. High health literacy is associated with higher cognitive performance and lower health-related quality of life. Physical, psychological, and social impairments are seen in chronic obstructive pulmonary disease (COPD). Studies investigating the relationship between health literacy and functional capacity, quality of life, physical activity, cognitive function, health-related behavior, and activities of daily living in individuals with COPD are limited. Therefore, the aim of this study was to compare individuals with COPD with healthy individuals in terms of health literacy, functional capacity, quality of life, physical activity, cognitive function, health-related behavior, and activities of daily living and to investigate the relationship between health literacy and functional capacity, quality of life, physical activity, cognitive function, health-related behavior, and activities of daily living in individuals with COPD.",[28,509,510],"Health Literacy","Health-Related Behavior","2026-06-24",{"date":513,"type":33},"2026-06-25",{"date":515,"type":33},"2024-06-15",{"date":517,"type":22},"2027-06-15",{"name":519,"class":73},"Hacettepe University",{"id":521,"slug":522,"hasResults":12,"nctId":523,"briefTitle":524,"officialTitle":525,"acronym":4,"eligibilityCriteria":526,"healthyVolunteers":12,"sex":17,"minAge":527,"maxAge":4,"enrollmentInfo":528,"targetDuration":4,"studyType":23,"phases":530,"briefSummary":531,"conditions":532,"keywords":533,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":537,"lastUpdatePostDateStruct":538,"startDateStruct":540,"completionDateStruct":542,"leadSponsor":544,"locationsCount":267},"100610040","closed-loop-oxygen-control-in-chronic-obstructive-pulmonary-disease-copd-patients-treated-with-nasal-high-flow-in-the-hospital-100610040","NCT07222410","Closed Loop Oxygen Control in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Nasal High Flow in the Hospital","Closed Loop Oxygen Control in COPD Patients Treated With Nasal High Flow in the Hospital","Inclusion Criteria:\n\n* Has cognitive ability to provide informed consent\n* Aged 22 years or older\n* Hospitalized with hypoxemia\u002Frespiratory distress\n* Diagnosis of COPD\n* Candidate for\u002Fcurrently prescribed nasal high flow (flow rate of at least 25 L\u002Fmin) with supplemental oxygen, as assessed by the investigator\n* Expected duration of oxygen and nasal high flow therapy \\>24 hours (not necessarily continuous)\n\nExclusion Criteria:\n\n* Receiving Non Invasive Ventilation (NIV) or indicated for NIV as per European Respiratory Society \u002FAmerican Thoracic Society guidelines\n* Hemodynamic instability (systolic blood pressure \\\u003C90mmHg or requirement for vasopressor or inotropic support)\n* Patient receiving end of life care\n* Nasal or facial conditions precluding use of nasal high flow\n* Pregnancy or breastfeeding\n* Cognitive impairment or impaired consciousness precluding informed consent\n* Unsuitable for adhesive finger pulse oximetry, as assessed by the investigator\n* Any other condition which, at the investigator's discretion, is believed to present a safety risk to the patient if included\n* The presence of any active comorbidities that affect the patient's condition importantly in the next 30 days, as assessed by the investigator\n* Has already participated in this clinical trial","22 Years",{"count":529,"type":22},70,[53],"The trial aims to evaluate whether the Airvo 3 device in OptiO2 mode can maintain patients' SpO2 levels within the target range better than manual oxygen titration in hospitalized COPD patients with hypoxemia\u002Frespiratory distress.",[28],[28,534,535,536],"closed loop oxygen control","hypoxemia","nasal high flow","2026-06-21",{"date":539,"type":33},"2026-06-23",{"date":541,"type":33},"2026-01-07",{"date":543,"type":22},"2027-11",{"name":545,"class":40},"Fisher and Paykel Healthcare",{"id":547,"slug":548,"hasResults":12,"nctId":549,"briefTitle":550,"officialTitle":551,"acronym":4,"eligibilityCriteria":552,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":553,"targetDuration":4,"studyType":23,"phases":555,"briefSummary":556,"conditions":557,"keywords":558,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":562,"lastUpdatePostDateStruct":563,"startDateStruct":564,"completionDateStruct":566,"leadSponsor":568,"locationsCount":74},"100493691","effect-of-combined-endurance-training-on-adl-and-walking-in-copd-patients-100493691","NCT05708443","Effect of Combined Endurance Training on ADL and Walking in COPD Patients","Effect of Combined Upper and Lower Extremity Endurance Training Versus Lower Extremity Training Alone on ADL and Walking in COPD Patients","Inclusion Criteria:\n\n* GOLD class 2-3 COPD\n* Forced Expiratory Volume in the first second (FEV1) between 30% and 70% of the predicted value\n* ability to walk and climb stairs without assistance\n* stable clinical condition (pH \\> 7.35)\n\nExclusion Criteria:\n\n* chronic respiratory insufficiency on long-term oxygen therapy (LTOT)\n* severe orthopedic, neurological or cardiological comorbidities\n* cognitive impairment\n* recent exacerbation (within 15 days) requiring a change in therapy\n* presence of lung disease other than COPD\n* terminality",{"count":554,"type":22},36,[53],"Chronic Obstructive Pulmonary Disease (COPD) is a chronic disease with related exercise intolerance and marked disability due to symptoms such as dyspnea and fatigue. Effort intolerance and exercise-induced symptoms cause marked impairment in completing activities of daily living (ADL). Pulmonary rehabilitation (PR), which has exercise as a major component, is considered a key treatment in the management of COPD since PR is effective in improving exercise tolerance, exercise-induced dyspnea and fatigue, and health-related quality of life. Rehabilitation is also effective in improving the time required to perform ADLs, reducing symptoms and disability. Studies show that rehabilitation protocols with upper limb exercises added to lower limb training are able to give additional benefits in terms of effort tolerance (endurance time at the arm ergometer and oxygen consumption) and reduction of dyspnea at iso-load.\n\nThe primary aim of this study is to evaluate whether the combined \"arm and leg\" training modality, compared to a gold standard protocol -involving only the lower limbs training- is more effective in improving ADL performance in terms of reduction of exercise time for a specific test (GLITTRE test).",[28],[559,28,560,561],"ADL","Glittre Test","exercise","2026-06-19",{"date":511,"type":33},{"date":565,"type":33},"2023-01-10",{"date":567,"type":22},"2027-06-30",{"name":569,"class":73},"Istituti Clinici Scientifici Maugeri SpA",{"id":571,"slug":572,"hasResults":12,"nctId":573,"briefTitle":574,"officialTitle":575,"acronym":576,"eligibilityCriteria":577,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":578,"targetDuration":4,"studyType":23,"phases":580,"briefSummary":581,"conditions":582,"keywords":584,"overallStatus":172,"whyStopped":4,"lastUpdateSubmitDate":588,"lastUpdatePostDateStruct":589,"startDateStruct":590,"completionDateStruct":591,"leadSponsor":593,"locationsCount":41},"100639765","copd-flare-up-clinic-after-severe-exacerbations-100639765","NCT07629869","COPD Flare-Up Clinic After Severe Exacerbations","The Role of COPD Flare-up Clinic Service After Severe Exacerbations to Reduce Recurrent Exacerbations","FLARE-COPD","Inclusion Criteria:\n\n* Prior COPD diagnosis based on clinical and spirometry accepted criteria.\n* Acute exacerbation of COPD as the main reason for ED arrival.\n* Ability to perform in-person and telephone follow-up.\n* Agree to participate, with a signed informed consent.\n\nExclusion Criteria:\n\n* Symptomatic heart failure as the main reason for emergency department visit in the last 6 months.\n* Uncontrolled comorbidity.\n* Vulnerable Populations: To ensure ethical compliance and participant safety, the study will exclude vulnerable populations. This includes pregnant women, and any person lacking the mental or legal capacity to provide independent informed consent.",{"count":579,"type":22},240,[53],"This prospective randomized controlled trial evaluates whether a specialized \"COPD flare-up clinic service\" improves outcomes in patients following an acute exacerbation of chronic obstructive pulmonary disease (AECOPD). Patients presenting to the emergency department with AECOPD and discharged or hospitalized will be randomized 1:1 to either structured follow-up in a dedicated flare-up clinic or standard follow-up by scheduled telephone interviews.\n\nThe researches hypothesize that structured follow-up in a specialized clinic will reduce recurrent exacerbations, optimize long-term COPD management, and improve patients' quality of life compared to standard care.",[28,583],"COPD Exacerbation (AECOPD)",[585,586,587],"COPD management","COPD flare-up","COPD exacerbation","2026-06-18",{"date":539,"type":33},{"date":470,"type":22},{"date":592,"type":22},"2028-12-31",{"name":594,"class":595},"Tel-Aviv Sourasky Medical Center","OTHER_GOV",{"id":597,"slug":598,"hasResults":12,"nctId":599,"briefTitle":600,"officialTitle":601,"acronym":602,"eligibilityCriteria":603,"healthyVolunteers":12,"sex":17,"minAge":604,"maxAge":19,"enrollmentInfo":605,"targetDuration":4,"studyType":23,"phases":607,"briefSummary":608,"conditions":609,"keywords":610,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":588,"lastUpdatePostDateStruct":615,"startDateStruct":616,"completionDateStruct":618,"leadSponsor":620,"locationsCount":622},"100530021","trial-evaluating-the-rate-of-pneumothorax-in-severe-emphysema-secondary-to-endoscopic-volume-reduction-with-two-stage-zephyr-valves-versus-endoscopic-volume-reduction-with-one-stage-zephyr-valves-100530021","NCT06181357","Trial Evaluating the Rate of Pneumothorax in Severe Emphysema Secondary to Endoscopic Volume Reduction With Two-stage ZEPHYR® Valves Versus Endoscopic Volume Reduction With One-stage ZEPHYR® Valves","Randomized Trial Evaluating the Rate of Pneumothorax in Severe Emphysema Secondary to Endoscopic Volume Reduction With Two-stage ZEPHYR® Valves Versus Endoscopic Volume Reduction With One-stage ZEPHYR® Valves","REPEAT","Inclusion Criteria:\n\nPatient able to give informed consent and participate in the study\n\n* Age ≥ 35 years old and ≤ 80 years old at the time of signing the consent\n* Emphysema (homogeneous or heterogeneous) on a recent CT scan (\\\u003C 6 months). Heterogeneous emphysema defined by a difference of at least 15% destruction (threshold 910HU) between two adjacent lobes.\n* Destruction ≥ 50% (threshold 910 HU) of the target lobe on the chest scanner\n* Smoking quit for 3 months\n* Dyspnea ≥ 2 according to the modified Medical Research Council (mMRC) questionnaire)\n* Post-bronchodilator FEV between 15 and 50% theoretical\n* Post-bronchodilator total lung capacity ≥ 100% theoretical and post-bronchodilator residual volume ≥ 175% theoretical\n* Distance traveled during the TM6M ≥ 100m\n* Member of or beneficiary of a social security scheme\n\nExclusion Criteria:\n\n* Asthma considered as main diagnosis\n* Recurrent exacerbations: (\\>3 over the last year or 2 requiring hospitalization)\n* Myocardial infarction or stroke in the 6 months prior to inclusion\n* Symptoms of heart failure in the 6 months prior to inclusion\n* Chest CT abnormalities: giant bulla (occupying more than a third of the pulmonary field), paraseptal emphysema, pulmonary nodule greater than 0.8cm (not applicable pulmonary nodules known for more than a year and stable), fibrosing interstitial pneumonitis, dilated bronchi\n* Pulmonary tomoscintigraphy:\n\n  * Patients for whom the least perfused lobe is not the one with the highest emphysema destruction score\n  * Patients with homogeneous emphysema for whom the perfusion delta (difference in perfusion between the ipsilateral lung and the treated lobe) is less than 10%\n* Arterial blood gas analysis in ambient air: Hypoxemia in ambient air (PaO2 \\\u003C 45 mmHg). Hypercapnia (PaCO2 \\> 55 mmHg)\n* Echocardiography:\n\n  * Left Ventricular Ejection Function \\\u003C 45%\n  * Systolic pulmonary arterial pressure \\> 45 mmHg\n* History of pneumonectomy, lung surgery homolateral to the lobe targeted for endoscopic lung volume reduction\n* History of pneumothorax homolateral to the lobe targeted for endoscopic lung volume reduction\n* History of endoscopic volume reduction\n* Oral corticosteroid therapy \\> 20 mg\u002Fday within the 4 weeks preceding inclusion\n* Symptomatic bronchial dilatations, bronchial colonization with pseudomonas aeruginosa, multi-resistant bacteria or aspergillus origin\n* Metastatic cancer undergoing treatment or whose treatments ended less than 5 years ago\n* Pregnant or breastfeeding women\n* Nickel allergy\n* Patient under guardianship, curatorship or under judicial protection\n* Participation in another interventional clinical research\n* Any other condition which, in the opinion of the investigator, could interfere with the objective of the study or would cause the subject's participation in the study to be suboptimal, in particular (non-exhaustive list) unweaned alcoholism, substance abuse, non-compliance with usual follow-up visits)\n\nsecondary exclusion criteria:\n\n\\- Evidence of collateral ventilation measured by the Chartis system","35 Years",{"count":606,"type":22},244,[53],"Chronic obstructive pulmonary disease (COPD) affects 3.5 million people and is the third leading cause of death worldwide. Emphysema involves air retention in the lungs and is ultimately responsible for a major deterioration in the quality of life. Available drug treatments have moderate efficacy whereas surgical lung volume reduction can improve exercise capacity when offered to a very selected population but at the cost of significant morbidity and mortality.\n\nEndoscopic Lung Volume reduction with ZEPHYR® valves improves respiratory function at rest, exercise tolerance and quality of life in patients with little or no interlobar collateral ventilation.\n\nIf this technique has therefore proven its effectiveness, it is not devoid of complications and is notably responsible for pneumothorax in 27% of cases. The management of this complication is clearly codified, ranging from patient monitoring to the removal of one or more valves. It is therefore a subject of major concern for multiple reasons: high incidence, lengthening of hospital stay, increase in the overall cost of care, potential loss of benefit for the patient in the event of permanent withdrawal. valves and above all a potentially fatal event.\n\nA new strategy for implanting ZEPHYR® valves in two stages has been developed in Limoges University Hospital. This innovative algorithm has been evaluated in several non-comparative single or multicenter studies. In those studies, pneumothorax' rate secondary to lung volume reduction with endobronchial valves is rated between 4.5 and 12%. The efficacy of the treatment appears to be comparable with the data found in the trials evaluating in which the entire lobe was treated in one procedure. Moreover, despite two procedures, there does not seem to be any increased risk of occurrence of other complications. Finally, the systematic scheduling of a thoracic computed tomography between the two procedures showed that 26.6% of patients presented a reduction in volume greater than 350mL despite incomplete treatment.\n\nThese data seem promising but no direct comparison with standard one-step treatment has ever been conducted so far.",[28],[611,612,613,614,28],"Endobronchial Zephyr® valves","Endoscopic lung volume reduction","Pneumothorax","Emphysema",{"date":539,"type":33},{"date":617,"type":33},"2024-05-06",{"date":619,"type":22},"2029-06-06",{"name":621,"class":73},"University Hospital, Limoges",17,{"id":624,"slug":625,"hasResults":12,"nctId":626,"briefTitle":627,"officialTitle":628,"acronym":4,"eligibilityCriteria":629,"healthyVolunteers":12,"sex":17,"minAge":83,"maxAge":630,"enrollmentInfo":631,"targetDuration":4,"studyType":23,"phases":633,"briefSummary":634,"conditions":635,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":636,"lastUpdatePostDateStruct":637,"startDateStruct":639,"completionDateStruct":641,"leadSponsor":643,"locationsCount":41},"100560515","physiologic-effects-of-nasal-high-flow-on-exercise-tolerance-in-copd-100560515","NCT06578156","Physiologic Effects of Nasal High Flow on Exercise Tolerance in COPD","Physiologic Effects of Nasal High Flow on Exercise Tolerance in Chronic Obstructive Pulmonary Disease (COPD)","Inclusion Criteria:\n\n* Able to consent\n* Age 18 years or older\n* Diagnosis of COPD\n* Ability to ambulate without assistance\n* Use of low-flow nasal cannula ≤ 4 L\u002Fmin or no supplemental oxygen (O2) at all\n\nExclusion Criteria:\n\n* Pregnancy\n* Being on bedrest\n* Inability to consent or cooperate with the study\n* Using of \\> 4 L\u002Fmin of supplemental O2 or requiring non-invasive ventilation during the daytime\n* Hemodynamic instability (resting heart rate \\> 130\u002Fminute, systolic blood pressure of ≤ 90 mmHg or ≥ 180 mmHg)\n* Metal implants in the thoracic regions (pacemakers, Automatic Implantable Cardioverter Defibrillator (AICD), plates, screws, rods, and disc replacements)","100 Years",{"count":632,"type":22},45,[53],"This study aims to assess whether to describe the effects of the administration of nasal high flow (NHF) at 70 liters per minute (L\u002Fmin) in a 6-Minute Walk Test (6-MWT) among Chronic Obstructive Pulmonary Disease (COPD) patients and to characterize the association between self-reported dyspnea with and without NHF at 70 L\u002Fmin following a 6-MWT.",[28],"2026-06-17",{"date":638,"type":33},"2026-06-22",{"date":640,"type":33},"2024-12-12",{"date":642,"type":22},"2027-12-31",{"name":644,"class":73},"University of Miami"]